Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 04/27/26
JPMorgan Initiates Hims & Hers With Overweight: Could the Novo Nordisk Deal Be the Turning Point?24/7 Wall Street • 04/24/26
Why Hims & Hers Health, Inc. (HIMS) is a Top Growth Stock for the Long-TermZacks Investment Research • 04/23/26
Stock Market Today, April 21: Hims & Hers Health Drops as Amazon Unveils Competing Weight Loss ProgramThe Motley Fool • 04/21/26
Hims & Hers Builds Scalable Data-Driven Personalized Care PlatformZacks Investment Research • 04/21/26
Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal24/7 Wall Street • 04/20/26
Hims & Hers Health (HIMS) Soars 11.1%: Is Further Upside Left in the Stock?Zacks Investment Research • 04/17/26
Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide TherapiesThe Motley Fool • 04/16/26
Hims & Hers shares jump as FDA begins review of restricted peptide compoundsProactive Investors • 04/16/26
HIMS Plunges 51.2% in 6 Months: Should You Still Hold the Stock or Sell?Zacks Investment Research • 04/16/26
BofA Raises Hims & Hers Target to $25 as FDA Takes a Step Toward Wellness Peptides: Is a New Revenue Boom Coming?24/7 Wall Street • 04/16/26
Hims & Hers Spikes; Will The FDA Blow The Door Open On Peptide Compounding?Investors Business Daily • 04/16/26
Hims & Hers Health Stock Rallies on Regulatory Pivot. It's Not About GLP-1s This Time.Barrons • 04/16/26